Novirin and Gene-Eden-VIR are natural antiviral products. Their formula was designed to help the immune system target the latent form of CMV. - Mike Evans, polyDNA
Rochester, NY (PRWEB) May 01, 2014
Pregnant women who kiss toddlers on the mouth risk acquiring the human cytomegalovirus (CMV) and then transmitting it to their unborn babies (1). In fact, for a full 9 months, pregnant women should be “more cautious in regards to the spread of disease (1).” polyDNA therefore recommends that women who want to guard against a CMV infection talk to their doctors about Novirin when planning a pregnancy. The formula of this natural antiviral targets the latent CMV, and was recently proven to reduce symptoms of a CMV infection in a post-marketing clinical study that followed FDA guidelines.
In addition, science shows that mothers with a latent CMV infection are just as dangerous to their newborn as those with an active CMV infection. For many years, it was thought that children born to mothers with an active CMV infection were at the highest risk of being born with symptomatic CMV disease. However, recent studies have shown that even when the mother has a latent CMV infection, the risk to the newborn is similar. Researchers wrote that “symptomatic infection occurs with similar frequency in children born to women with primary CMV infection and those born to women who were CMV seroimmune (that is, the mother has a latent CMV infection) before pregnancy. In addition, the severity of newborn disease and the rates of CMV-associated SNHL also do not differ between primary and nonprimary (latent) infection groups.” (See Clinical Infectious Diseases, from December 2013) (2).
Congenital cytomegalovirus disease is a group of symptoms that occur when a baby is infected with the CMV before birth. “For pregnant women, the most common exposures to CMV are through contact with the saliva and urine of young children or through sexual contact. Young children can transmit CMV for months after they first become infected. However, CMV does not spread easily. (Only) one in 5 parents of children who have active CMV infections become infected with CMV over the course of a year.” (See the CDC’s website, last updated on June 24, 2013) (3).
Primary infection of the mother is much more dangerous than a recurrent infection. “Infants born congenitally infected with CMV as a result of a primary maternal infection also are much more likely to have symptoms at birth and suffer sequelae (symptoms) than newborns born congenitally infected from a maternal recurrent CMV infection.” (See Uptodate.com, last updated on February 26, 2014) (4). The most susceptible newborns are those with a weak immune system. “Newborns with a primary immune disorder of cellular function (eg, severe combined immune deficiency or natural killer (NK) cell disorders) may also manifest severe or fatal congenital CMV infection (4).”
“In the United States, more than 5,000 children suffer illness and permanent disabilities caused by congenital CMV infection every year, although many infants - about 80 out of 100 - with congenital CMV infection never develop symptoms or disabilities from the infection. Children with congenital CMV infection are more likely to have permanent disabilities if they had symptoms of CMV infection at birth. However, some children with congenital CMV infection who appear healthy at birth can develop hearing or vision loss over time (3).” Additionally, as noted above, young babies can succumb to the virus and die.
The information above is presenting two important questions.
First, what can mothers do to reduce the effect of an active CMV infection?
There are some drugs approved for use against an active CMV infection. However, most of these are used exclusively in immunocompromised individuals (such as those with HIV). In healthy people these drugs are “limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (See Pharmacology & Pharmacy, from September 2013) (5).
Second, what can mothers do to reduce the effect of a latent CMV infection?
As far as we know, the only two products currently available that target the latent CMV are Gene-Eden-VIR, and Novirin.
“Novirin and Gene-Eden-VIR are natural antiviral products. Their formula was designed to help the immune system target the latent form of CMV. This means it goes after the virus before it becomes active and causes symptoms. We therefore recommend that women planning a pregnancy speak to their doctors about Novirin.” - Mike Evans, polyDNA
Novirin shares the same formula as Gene-Eden-VIR. The difference between the two is that Novirin has higher quality, more expensive ingredients. The Novirin/Gene-Eden-VIR formula was tested in two post-marketing clinical studies published in September 2013 and March 2014, respectively, in the peer reviewed medical journal Pharmacy & Pharmacology (5).
Interested individuals can view the two published studies here, http://cbcd.net/Gene-Eden-VIR-Clinical-Study.php and http://cbcd.net/Gene-Eden-VIR-Decreases-Fatigue-Clinical-Study.php.
Up to 70% of those studied reported a decrease in symptoms associated with CMV infection, and users of the Novirin/Gene-Eden-VIR formula experienced an increase in overall health (5).
Each ingredient of Novirin was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the highest quality, safest, most effective natural ingredients that target latent viruses.
A second clinical study showed that the Novirin/Gene-Eden-VIR formula decreased physical and mental fatigue. (See Pharmacology & Pharmacy, from March, 2014) (6).
To learn more about Novirin, visit http://www.novirin.com and about Gene-Eden-VIR, visit http://www.gene-eden-vir.com.
All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
References:
(1) Mother On A Mission To Stop Birth Defects. Published on April 28, 2014.
http://foxct.com/2014/04/28/mother-on-a-mission-to-stop-birth-defects/
(2) Congenital cytomegalovirus infection: clinical outcome. Published December 2013.
http://www.ncbi.nlm.nih.gov/pubmed/24257422
(3) CDC - Cytomegalovirus: Protect Your Baby. Last updated on June 24, 2013.
http://www.cdc.gov/features/cytomegalovirus/
(4) Cytomegalovirus infection and disease in newborns, infants, children and adolescents. Last updated February 26, 2014.
http://www.uptodate.com/contents/cytomegalovirus-infection-and-disease-in-newborns-infants-children-and-adolescents
(5) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013. cbcd.net/Gene-Eden-VIR-Clinical-Study.php
(6) Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory. Published in March 2014. cbcd.net/Gene-Eden-VIR-Decreases-Fatigue-Clinical-Study.php
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Novirin, an antiviral natural remedy that helps the immune system kill latent viruses.